9th Annual Biomarkers Congress

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2010 Disease-free survival at 2 or 3 years correlates with 5-year overall survival inpatients undergoing radical cystectomy for muscle-invasive bladder cancer. to be submitted to J Clin Oncol)
2. 2010 Hexaminolevulinate-guided fluorescence cystoscopy reduces recurrence in patients with non-muscle invasive bladder cancer. J Urol 2010 (accepted)
3. 2010 Influence of HLA-A and B cross-reactive antigen matching on kidney graft survival. Tissue Antigens. l8:l0l-l04, l98l.
4. 2010 p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int 105:489-495, 2010.
5. 2010 Characteristics and outcomes of patients with pT4 urothelial urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol 183:87-93, 2010.
6. 2010 Combination of multiple molecular markers can improve prognostication in patients withylocally advanced and lymph node positive bladder cancer. J Urol 183: 68-75, 2010
7. 2010 BCAN Think Tank session 2: Molecular detection of bladder cancer: the path to progress Urol Oncol 28:334-337, 2010.
8. 2010 Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes J Clin Pathol 2010 (in press).
9. 2010 Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: Results from an international cohort Eur Urol 57:300-309, 2010.
10. 2010 Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc. Natl. Acad. Sci. USA 8l:224, 228, l984
11. 2010 Molecular urine tests for the diagnosis of prostate cancer, Chapter 58, in: Prostate Cancer: Principles and Practice Taylor & Francis 2006, pp. 585-591.
12. 2010 Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. Eur. Urol 2010 (in press).
13. 2010 Cell surface antigens of human teratocarcinoma cell lines analyzed by monoclonal antibodies. In Cold Spring Harbor Conference on Cell Proliferation, Vol l0:, Teratocarcinoma Stem Cells, p. 59l, l983.
14. 2010 Immunoanatomic dissection of the human urinary tract by monoclonal antibodies. J. Histochem. Cytochem. 32:l035-l040, l984.
15. 2010 Total androgen blockade in stage D2 prostatic cancer: a randomized trial. Am. J. Clin. Oncol. 11, Suppl.2: S187-S190, 1988.
16. 2010 Salvage therapy with bicalutamide 150 mg in non metastatic castration-resistant prostate cancer. Urology (in press).
17. 2010 Immunological activities of rat lymphocytes. II. Isolation of suppressor cells of the mitogenic response of rat thoracic duct lymphocytes Cell. Immunol. 17: 123 130, l975.
18. 2010 Le traitement du cancer localise de la prostate par implantation d'iode radioactif. Un. Med. Can., 114: 737, 739, l985.
19. 2010 Regulation of in vitro lymphocytes responses. A. Cell. Immunol. 27: 94, 101
20. 2010 Atudes de certaines proprietes du lymphocytes T inhibiteur. Rev. Med., XVII: 1691, 1692, l976.
21. 2010 Modulation de la proliferation lymphocytaire par des facteurs seriques et le lipopolysaccharide. Ann. Immunol. (Inst. Pasteur), l28C: 33, 35, l977.
22. 2010 Activites immunologiques des lymphocytes de rat. IV. Variation fonctionnelle chronologique des lymphocytes du canal thoracique Un. Med. Can. 106: 951, 955
23. 2010 Enhanced prostaglandins E2 in postobstructive diuresis in humans. Prostaglandins Med. 5:29, 30, l980.
24. 2010 Kidney graft survival. Role of blood transfusions and lymphocytic antibodies. Clin. Nephr. l8:69, 73, l982.
25. 2010 Characterization of lymphocytotoxic antibodies in renal transplantation. Transplant. 3l:3l, 33, l98l.
26. 2010 Intravesical administration of BCG alters detection of a urothelial differentiation antigen in exfoliated cells of carcinoma in situ of human urinary bladder. Cancer Res., 45: 520l, 5204, l985.
27. 2010 Soft tissue surgical margin status is a powerful predictor of outcomes after raadical cystectomy: a multicenter study of over 4,400 patients J Urol (in press).
28. 2010 International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy BJU Int (in press).
29. 2010 Role of prostaglandins E2 and F2a in the physiopathology of postobstructive diuresis. Prostaglandins Leuk. Essential Fatty Acids 31: 123, 129, l988.
30. 2010 Apport de la fluxcytometrie a  paramatres multiples a  la detection et a  l'Evaluation des tumeurs vaƒesicales humaines Un. Med. Can., 114: 778:780, l985
31. 2010 Evaluation of fluorodeoxyglucose positron-emisson tomography with computed tomography for staging of urothelial carcinoma BJU Int 2010 (in press).
32. 2010 Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. Submitted
33. 2010 Multi-institutional evaluation of the predictive value of p53 expression in patients with pT1-2 N0 disease at radical cystectomy. Submitted to J Clin Oncol.
34. 2009 Early detection of prostate cancer local recurrence by urinary prostate-specific antigen CUAJ 3: 213-217, 2009.
35. 2009 Survivin as a prognostic marker for urothelial carcinoma of the bladdder a multicenter external validation study Clin Cancer Res 15:7012-7019, 2009.
36. 2009 Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to Bacillus Calmette-Guerin Immunotherapy. Eur Urol 55:1386-1396, 2009.
37. 2009 International Bladder Cancer Nomogram Consortium. Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach. Cancer 115: 5460-5469, 2009.
38. 2009 Prostate cancer gene 3 (PCA3): Development and internal validation of a novel biopsy nomogram Eur J Urol 56: 659-667, 2009.
39. 2009 Screening for bladder cancer: the best opportunity to reduce mortality Can Urol Assn J 3: S180-S183, 2009.
40. 2009 Arguments agains investing widely in robotic prostatectomy in Canada: a wrong focus on tool box rather than surgical expertise. CanUrol Assn J 3: 486-487, 2009.
41. 2009 Predictive value of combined immunohistochemichal markers in patients with pT1 urothelial carcinoma at radical cystectomy J Urol 192:78-84; discussion 84, 2009.
42. 2009 High frequency of MAGE-A4 and MAGE-A9 expression in high risk bladder cancer. Int J Cancer 125: 1365-1371, 2009.
43. 2009 Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality. Cancer 115: 2853-2862, 2009.
44. 2009 p53 predictive value for pT1-2 N0 disease at radical cystectomy J Urol 182:907-913, 2009
45. 2009 Gleason grading controversies: what the chemopretention trials have taught us CUAJ Supplement on prostate cancer 3:S115-120, 2009.
46. 2009 The burden of prostate cancer in Canada CUAJ Supplement on prostate cancer 3:S92-100, 2009.
47. 2009 Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. Curr Opin Urol 19: 243-246, 2009.
48. 2009 Multi-institutional external validation of the predictive value of Ki-67 labeling index in patients treated with radical cystectomy. J Natl Cancer Inst 101:114-119, 2009.
49. 2008 Grossman HB. Bladder cancer markers in patient management: the current perspective World J. Urol 26: 1-3, 2008.
50. 2008 Tissue factor expression correlates with disease-specific survival in patients with muscle-invasive bladder cancer treated by radical cystectomy Int. J. Cancer 122: 1592-1597, 2008.
51. 2008 Maintenance bacillus Calmette-Guerin in high-risk nonmuscle-invasive bladder cancer: how much is enough? Cancer 113: 710-716, 2008.
52. 2008 Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry. Hum Pathol 39: 731-739, 2008.
53. 2008 The management of high-risk prostate cancer in 2008 Editorial World J. Urol 26: 203, 2008.
54. 2008 Substrafication of high-risk localised prostate cancer treated by radical prostatectomy. World J Urol 26: 225-229, 2008.
55. 2008 The detection of genetic markers of bladder cancer in urine and serum Curr Opin Urol 18 499-503, 2008.
56. 2008 Invasive bladder cancer: time is of the essence. Can Urol Assoc J, 2:109, 2008.
57. 2008 Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin. Clin Cancer Res 14:1510-1518, 2008.
58. 2008 PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179: 1587-1592, 2008.
59. 2007 Identification of PCA3 (DDA) in prostatic carcinoma by in situ hybridization. Modern Pathol 20: 1121-1127, 2007.
60. 2007 Urinary PSA, a potential useful marker when serum PSA is between 2.5 and 10 ng/ml. Can Urol Assoc J 1:377-381, 2007.
61. 2007 Devrait-on offrir aux Canadiens le depistage systematique du cancer de la prostate? Canadian Family Physician/Le Medecine de famille canadien 53 : 994-996, 2007.
62. 2007 MAGE-A9 mRNA and protein expression in bladder cancer. Int. J. Cancer 120:2170-2177, 2007.
63. 2007 Devrait-on offrir aux Canadiens le depistage systematique du cancer de la prostate? Canadian Family Physician/Le Medecine de famille canadien. 53 : 1142-1143, 2007.
64. 2007 Urologic Paraneoplastic Syndromes. In : Emergencies in Urology. Ed., M. Hohenfellner and R. Santucci. Springer 2007, pp. 172-182
65. 2007 Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with Bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose response study Eur Urol 52: 106,115, 2007.
66. 2007 PD-L1 (B7-H1) and urothelial carcinoma of the bladder and BCG-induced granulomata: aassociations with localized stage progression Cancer 109: 1499-1505, 2007.
67. 2007 PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69:532-535, 2007.
68. 2007 A phase III, multicenter comparison of hexaminolevulinate (HAL) fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer J Urol 178: 62-67, 2007.
69. 2007 comparison of hemaminolevulinate (HKL) fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer. J Urol 178:68-73, 2007.
70. 2006 Cancer-testis antigen expression in bladder cancer. Progres Urol. 15: 1303-1313, 2005. Erratum Prog. Urol. 16: 421-428, 2006.
71. 2006 Cytology and tumor markers: tumor markers beyond cytology. In: Bladder Tumors. Ed. Mark Soloway, Adrienne Carmack, Saad Khoury. 1st International Consultation on Bladder Tumors Hawaii, October 3-7, 2004. pp. 67-137, 2006.
72. 2006 Postoperative nomogram predicting risk of recurrence following radical cystectomy for bladder cancer. J Clin Oncol 24: 3967-3972, 2006.
73. 2006 Bladder tumor markers beyond cytology. Bladder Cancer Consensus Panel. Urology 66: 35-64, 2006.
74. 2006 Prognostic markers for bladder cancer: Bladder Cancer Consensus Panel. Urology 66: 64-74, 2006.
75. 2006 Does prolonging the time to bladder cancer surgery affect long-term cancer control: a systematic review of the literature Can J Urol 13: Suppl. 3: 37-47, Review, 2006.
76. 2006 Prostatic intraepithelial neoplasia in TURP specimens and subsequent prostate cancer Can J Urol 13: 3255-3260, 2006.
77. 2006 Polymorphisms of the human NRAMP1 gene are associated with response to BCG immunotherapy in superficial bladder cancer. J Urol 175: 1506-1511, 2006.
78. 2005 Insomnia in men treated with radical prostactectomy for prostate cancer, Psycho-Oncology 14: 147-156, 2005
79. 2005 Psychological functioning associated with prostate cancer: cross-sectional comparison of patients treated with radiotherapy, brachytherapy or surgery. J Pain Symptom Manag. 30:474-484, 2005.
80. 2005 ImmunoCytTM improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Modern Pathol 18: 83-89, 2005.
81. 2005 Insulin-like growth factor binding protein 2 : an androgen-dependant predictor of prostate cancer survival Eur Urol, 47: 695-702, 2005.
82. 2004 Safety and outcome of early catheter removal following radical retropubic prostatectomy. Urology 63:513-517, 2004.
83. 2004 Accelarated induction of bladder cancer in Patched heterozygous mutant mice Cancer Res 64: 1938-1942, 2004.
84. 2004 Transurethral Surgery of Bladder Tumors In : Urologic Oncology (Drs Richies & DAmico s Book) Elsevier Science, 2004, Chapter 20, pp. 358-367.
85. 2004 A survey of urological manpower, resources, and technology in Canada. Can J Urol 11:2290-2295, 2004.
86. 2004 uPM3, a new molecular urine test for the detection of prostate cancer Urology 64:311-316,2004.
87. 2003 Expression of p21 cell-cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy. Prostate 58: 269-76, 2004.
88. 2003 Alteration of the Patched locus in superficial bladder cancer. Oncogene 22: 2967-2971, 2003
89. 2003 Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res 63 : 8511-8515, 2003.
90. 2003 Defining a 0.5 Mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction. Am. J. Pathol. 164:285-293, 2004.
91. 2003 La voie de signalisation PATCHED/Sonic Hedgehog dans le cancer superficiel de la vessie. Med. Sci 19: 920-925, 2003
92. 2003 Neoadjuvant hormonotherapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level. J. Urol. 170: 447-450, 2003
93. 2003 Bicalutamide (Casodex E) in the treatment of prostate cancer. Expert Rev Anticancer Ther 4: 37-48, 2004.
94. 2003 Routine nasogastric tubes are not required following cystectomy with urinary diversion a comparatiave analysis of 430 patients J. Urol 170: 1888-1891, 2003
95. 2003 Long term follow up of a randomised trial of 0 vs 3 months neoadjuvant androgen ablation prior to radical prostatectomy. J. Urol. 170: 791-794, 2003
96. 2002 Prognostic markers in muscle invasive bladder cancer World J Urol. 20:190-195, 2002
97. 2002 Recent advances in the management of superficial bladder tumors. Can. J. Urol. 9 :1544-1550, 2002.
98. 2002 Role of radical prostatectomy in high-risk prostate cancer Can. J. Urol. 9: 8-13, 2002.
99. 2002 Controversies in the management of localized prostate cancer : consensus development by Canadian urologists Can. J. Urol. 9: 30-35, 2002.
100. 2002 Current controversies in the management of prostate cancer Can J Urol 9: 1, 2002.
101. 2002 ImmunoCytTN improves the accuracy of urine cytology Histopathology 41: 403-413, 2002.
102. 2002 How to prevent prostate cancer. Dundesamt fer Gesundheit Dans: Cancer de la prostate: Connaitre et agir. Programme national de lutte contre le cancer. Office federal de la sante publique. 2002 pp. 58-60.
103. 2002 Diagnosis of bladder cancer. In: Bladder Cancer. Current Diagnosis and Treatment. Ed. M.J. Droller, Humana Press Inc., Totowa, NJ, 2002, pp.57-83
104. 2002 Insulin-like growth factor binding protein-5 (IGFBP-5) is differentially expressed upon different spatial configuration of MGH-U3 bladder cancer cells. Urologic Oncology 7:57-61, 2002.
105. 2002 Prostatectomie radicale de rattrapage apres Echec de la radiotherapie pour cancer localiseÆ’e de la prostate Revue de la litterature Progres en Urologie 12 : 1179-1187, 2002.
106. 2002 Marqueurs moleculaires du cancer infiltrant de la vessie. Progres en Urologie 12a : 1057- 1083, 2002
107. 2002 Does the potassium stimulation test predict cystometric and cystoscopic outcome in interstitial cystitis? J. Urol.168: 556-557, 2002.
108. 2002 New diagnostic and prognostic tools in bladder cancer. Curr. Opin. Urol. 12: 239-243, 2002.
109. 2001 International Mitomycin C Consortium. Methods to improve efficacy of intraveiscal mitomycin C: results of a phase III trial. J Natl Cancer Inst. 93: 597-604, 2001.
110. 2001 Predictors of patient response to antibiotic therapy for chronic prostatitis/chronic pelvic pain syndrome: prospective multicenter clinical trial J. Urol. 165:1539-1544, 2001
111. 2001 Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy . Int. J. Cancer 95: 135-139, 2001.
112. 2001 ImmunoCyt & bladder cancer: A urologist s perspective. DAKO connection. An educational resource for clinical diagnostics & research 3: 12-15, 2001.
113. 2001 p53 expression in superficial bladder cancer. Urol. Integr. Invest. 6:48-56, 2001.
114. 2001 Duration of neoadjuvant deprivation therapy prior to radical prostatectomy and disease-free survival in men with prostate cancer. Urology 58: 71-77, 2001.
115. 2000 National Cancer Institute Bladder Tumor Marker Network. Reproducibility of p53 immunohistochemistry in bladder tumors Clin. Cancer Res. 6: 1854-1864, 2000.
116. 2000 In: Comprehensive Textbook of Genitourinary Oncology 2nd Edition (N.J. Vogelzang, P.T. Scardino, W.U. Shipley, D.S. Coffey, Eds) Lippincott Williams & Wilkins, 2000, Chapter 16: 282- 288
117. 2000 Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest. Oncogene 19:6317-6323, 2000.
118. 2000 Canadian Urologic Oncology Group. Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b (rIFN-g) for the treatment of metastatic renal cell carcinoma (mRCC). BJU Int. 86:613-618, 2000.
119. 2000 p53 immunohistochemistry as a prognostic marker in bladder cancer Eur. Urol. 38: 691-700, 2000.
120. 2000 Use of markers in defining urothelial premalignant and malignant conditions. Scand. J. Urol. Nephrol. 205: 94-104, 2000.
121. 2000 Lifetime occupational physical activity and incidental prostate cancer Cancer Causes & Control 11: 759-764, 2000.
122. 2000 Can biological markers predict recurrence and progression of superficial bladder cancer. Curr. Opin. Urol.: 10: 441-445, 2000.
123. 2000 L echelle internationale de cotation des symptomes prostatiques . Le Medecin de Famille 46:1772-1776, 2000
124. 2000 Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis. J. Urol. 163:752-757, 2000.
125. 2000 Tumorigenic pathways in low stage bladder cancer based on p53, MDM2 and p21 phenotypes Int. J. Cancer 89: 100-104, 2000.
126. 2000 p53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers. Carcinogenesis 21: 101-106, 2000.
127. 1999 Low frequency of human papillomavirus infection in initial papillary bladder tumors Urological Research 28: 180-184, 1999
128. 1999 Screening In: Prostate Cancer, Ed. N.A. Iscoe, M.A.S. Jewett, Canadian Medical Association, 1999, Chapter 4; 35-42.
129. 1999 Deletions of the INK4A genes in superficial bladder tumors: Association with recurrence. Am. J. Pathol. 155: 105-113, 1999.
130. 1999 Dietary fat and prostate cancer progression and survival. Eur. Urol., 35: 388-391, 1999.
131. 1999 Blood management and radical retropubic prostatectomy: Quebec experience. Can J. Urol. 6: 727-731, 1999.
132. 1999 Genetic and molecular markers in the prognosis of bladder cancer Urol. Oncol. 4: 139-144, 1999.
133. 1999 Neoadjuvant hormonal therapy before radical prostatectomy and risk of PSA failure. J. Urol. 162: 2024-2028, 1999.
134. 1999 Predictive value of cell cycle markers p53, MDM2, p21 and Ki-67 in superficial bladder tumor recurrence Clin. Cancer Res. 5: 4079-4084, 1999.
135. 1999 A CUOG randomized trial of neoadjuvant androgen ablation prior to radical prostatectomy: 36 month post-treatment PSA results. Urology 53: 757-763, 1999.
136. 1999 Relationship between diet, prostate cancer established. Contribution to the Chronicle of Urology & Sexual Medicine October 1999, p. 4.
137. 1999 Downward trend in prostate cancer mortality in Quebec and Canada . J. Urol. 161: 1189-1191, 1999.
138. 1999 Electromotive drug administration (EMDA) of lidocaine as an alternative anesthesia for transurethral surgery. J. Urol., 161: 482-485, 1999.
139. 1999 Four tumor suppressor loci on chromosome 9q in bladder cancer : evidence for two novel candidate tumor suppressor genes at 9q22 and 9q31 Oncogene, 18 : 157-163, 1999.
140. 1999 Dietary fat and prostate cancer survival Cancer Causes & Control 10: 245-251, 1999.
141. 1999 Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors Human Pathol. 30: 1350-1355, 1999.
142. 1998 Randomized trial of neoadjuvant androgen ablation prior to radical prostatectomy: 24-month post-treatment PSA results Mol. Urol. 2:165-169, 1998.
143. 1998 Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. J. Urol. 159:925-928, 1998.
144. 1998 Morphologic effects of neoadjuvant hormone therapy on prostate cancer Mol. Urol. 2: 103-107, 1998
145. 1998 Prostate cancer: Screening. Can. Med. Assn J. 159: 968-972, 1998.
146. 1998 Dietary fat and risk of advanced prostate cancer. J. Urol. 159: 1271-1275, 1998.
147. 1998 Phase III randomized, double-blind, placebo-controlled, multicenter trial comparing interferon gamma to placebo in patients with metastatic renal cell carcinoma N. Engl. J. Med. 338:1265-1271, 1998.
148. 1998 Quebec prostate cancer mortality dropped in 1996. Cancer Prevention & Control 2: 163-166, 1998.
149. 1998 Canadian PROSPECT investigators. Placebo therapy of benign prostatic hyperplasia: a 25 month study Br. J. Urol. 81:383-387, 1998.
150. 1998 NCI Bladder Tumor Marker Network. Biomarker study of primary nonmetastatic versus metastatic invasive bladder cancer. Clin. Cancer Res. 4: 1267-1271, 1998.
151. 1998 A novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate Urology 52: 72-81, 1998.
152. 1998 The early clinical course of primary Ta and T1 bladder cancer: a prognostic index Brit. J. Urol. 81: 692-698, 1998.
153. 1998 SIU Symposium, Montreal, 1997. The role of antiandrogens in hormonal therapy. Contemporary Urology 10: 42-57, 1998.
154. 1998 Phenotypic characterization of bladder cancer. Eur. Urol. 33: 5-6, 1998.
155. 1997 Summary of effect of intravesical Bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder. Commentary by Fradet, Y. Sem. Urol. Oncol. 15: 80-55, 1997.
156. 1997 Prognostic factors: Back to the future In: Superficial Bladder Cancer, Ed. F. Pagano & W.R. Fair, ISIS Medical Media Ltd, Oxford, UK, 1997, Chapter 5; 57-70
157. 1997 Transurethral surgery of bladder tumors Philadelphia, USA, 1997, Chapter 19; 292-301.
158. 1997 Dietary energy and nutrients in relation to prostate cancer: a case-control study Nutrition and Cancer 29:120-126, 1997.
159. 1997 Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCytTM Can. J. Urol. 4:400-405, 1997.
160. 1997 Variability of DNA analysis by image cytometry. Cytometry, 28:176-180, 1997.
161. 1997 Influence of spatial configuration on the expression of CEA and mucin antigens in human bladder cancer. Int. J. Cancer 71:986-992, 1997.
162. 1997 The treatment of prostate cancer: how is failure defined and how can it be minimized Can. J. Urol. 4: 39-43, 1997.
163. 1997 Diagnostic accuracy of urinary cytology and DNA flow cytometry and cytology on bladder washings during follow-up for bladder tumors J. Urol.157: 1660-1664, 1997.
164. 1997 Tumor associated antigens in normal mucosa of patients with superficial transitional-cell carcinoma of the bladder Tumor associated antigens in normal mucosa of patients with superficial transitional-cell carcinoma of the bladder
165. 1997 Neoadjuvant hormonal therapy: the Canadian experience. Urology 49 (Suppl. 3A): 56-64, 1997.
166. 1997 Biochemical characterization of a bladder-cancer-associated mucin. Biochem. J. 321: 889-895, 1997
167. 1997 Interet clinique de letude d antigenes de proliferation et d activation cellulaire par cytometrie en flux dans le cancer de la vessie Progres en Urologie 6:907-912, 1997.
168. 1996 Principles and Practice of Genitourinary Oncology, J.B. Lippincott Company, 1996; Chapter 21; 231-238 Tumor markers in the management of bladder cancer.
169. 1996 Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 48: 47-57, 1996
170. 1996 Prognostic significance of nuclear DNA content and S phase fraction by flow cytometry in primary superficial bladder cancer Human Pathol 27:922-926, 1996
171. 1996 Detection of c-erB-2 and other tumor markers on bladder tumor specimens: marked differences after formalin or Bouin's fixation J. Exp. & Clin. Cancer Res. 15: 99-102, 1996
172. 1996 Issues and Controversies in prostate cancer - A consensus development conference. Proceedings of a roundtable conference held at the Fifth International Congress on Hormones and Cancer, Quebec New Jersey, USA, pp. 3-15, 1996.
173. 1996 Emerging prognostic and diagnostic tests for the management of bladder cancer Can. J. Urol. 3:27-34, 1996.
174. 1996 Criteria for conducting clinical trials in advanced prostate cancer Can.J. Urol. 3:96-99, 1996.
175. 1996 Prelavence and clinical significance of HER-2/neu, P53 and Rb expression in primary superficial bladder cancer J. Urol. 155: 1784-1788, 1996.
176. 1996 Toxicity of ribosome-inactivating proteins-containng immunotoxins to a human bladder carcinoma cell line Int. J. Cancer 65:485-490, 1996.
177. 1996 Superficial Bladder Cancer Symposium Contemporary Urol 8:61-74, 1996
178. 1996 Identification of a bladder tumor-associated glycoform of the carcinoembryonic antigen by monoclonal antibody 19A211 Cancer Res. 56:908-915, 1996.
179. 1996 MAUB, a new mucin antigen associated with bladder cancer. J. Biol. Chem. 271:6933-6941, 1996.
180. 1996 Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: a randomized study. Am. J. Surg. Pathol. 20:86-93, 1996.
181. 1996 The role of neoadjuvant androgen deprivation prior to radical prostatectomy. Urologic Clinics of North America. 23: 575-585, 1996
182. 1996 A multicentre, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology 47:355-342, 1996.
183. 1996 Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. J. Urol. 156: 873-877, 1996.
184. 1996 Efficacy and safety of Finasteride therapy for benign prostataic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study). Can. Med. Assoc. J. 155:1251, 1996.
185. 1996 Tests for recurrent bladder cancer debut in the U.S Guest editorial for Urology Times of Canada, August 1996.
186. 1995 CME update segment on positive surgical margins in carcinoma of the prostate. Video J. Urol. CME Update File, 1995
187. 1995 Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder Clin. Cancer Res. 1:1195-1202, 1995.
188. 1995 Treatment of superficial bladder cancer. Curr. Opin. Urol. 5:267-271, 1995.
189. 1995 The etiology of bladder cancer: are they any new clues or predictors of behavior? Int. J. Urol. 2:64-75, 1995.
190. 1995 Human papillomavirus in transitional cell carcinoma of the urinary bladder Clin. Cancer Res. 1:435-440, 1995.
191. 1995 Downstaging of localized prostate cancer by combination therapy with flutamide and an LHRH agonist before radical prostatectomy: the first randomized trial. Cancer Survey, 23: 149-156, 1995.
192. 1995 Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 45:491-497, 1995.
193. 1995 Prognostic value of EGF-R, T138, T43 expression in bladder cancer. Br J Cancer 71:196-200, 1995.
194. 1995 Epidemiology of bladder cancer. In: Comprehensive Textbook of Genitourinary Oncology Williams & Wilkins, 1995, Chapter 17: pp.299-304.
195. 1995 A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 45: 745-752, 1995.
196. 1995 La surrenalectomie ipsilaterale dans le traitement chirurgical du carcinome renal. Progres en Urologie 5:961-964, 1995.
197. 1994 Tumor-associated antigens might help urologists determine the likelihood of bladder cancer recurrence after treatment. AUA Today 7:1-2, 1994.
198. 1994 B. Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist Urology, 4:29-37, 1994.
199. 1994 Canadian Workshop on Screening for Prostate Cancer Proceedings. Suppl. Can., J. Oncology, Editors Y. Fradet and François Meyer. Vol. 4 Suppl. 1, november 1994.
200. 1994 Screening for prostate cancer. A urological perspective Can. J. Oncol. 4 (Suppl.1):8-12, 1994
201. 1994 NIH Marker Network for Bladder Cancer. Ha-ras codon 12 mutation in papillary tumors of the urinary bladder. A retrospective study. Int. J. Oncol. 4: 85-90, 1994.
202. 1994 Investigating urinary tract infections. Can. J. Continuing Medical Education 6: 33-46, 1994.
203. 1994 Influence of the diagnostic modality on pathological stage of clinically localised prostatic cancer. Can. J. Urol. 1: 34-38, 1994.
204. 1994 Bladder Marker Network. Blood group antigen expression in bladder tumors: an immunohistochemical study of superficial bladder lesions J. Exp. Clin. Cancer Res. 13: 139-144, 1994.
205. 1993 Field molecular epidemiology: feasibility of monitoring for the malignant bladder cell phenotype in a benzidine-exposed occupational cohort J. Occupational Med. 35:20-27, 1993.
206. 1993 Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial Clin. Invest. Med. 16: 499-509,
207. 1993 Flow and image cytometry for DNA analysis in bladder washings: improved concordance by using internal reference for flow. Cytometry 14: 943-950, 1993.
208. 1993 Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells. Cancer 72: 2461-2468, 1993.
209. 1993 Neo-adjuvant hormonal therapy prior to radical prostatectomy in localized prostate cancer. Symposium Proceedings of the Urologic Oncology Update, Puerto Rico, November 1993, pp.26-29.
210. 1993 Consensus review of the clinical utility of DNA cytometry in bladder cancer. Cytometry 14:478-481, 1993.
211. 1993 Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis. Proc. Natl. Acad. Sci. USA 90:8287-8291, 1993.
212. 1993 Critical appraisal of tumor markers in bladder cancer. Sem. Urol. 11:145-153, 1993.
213. 1992 Strategies of chemoprevention based on antigenic and molecular markers of early and premalignant lesions of the bladder J. Cell. Biochem. 161:85-92, 1992.
214. 1992 Intermediate endpoints markers for chemoprevention. J. Cell. Biochem. 161:93-110, 1992.
215. 1992 Antibody drug carrier for immunotherapy of superficial bladder cancer: ultrastructural studies Cancer Res. 52:3131-3137, 1992.
216. 1992 Radioimmunodetection of human bladder tumor xenografts in nude mice with radiolabeled monoclonal antibodies J. Urol. 148: 418-422, 1992.
217. 1992 Cell surface differentiation antigens of normal urothelium and bladder tumors Semin. Surg. Oncol. 8: 293-299, 1992.
218. 1992 Immunopathologic analysis of human urinary bladder cancer. Characterization of two new antigens associated with low-grade superficial bladder tumors. Am. J. Pathol. 140:375-385, 1992.
219. 1992 Markers of prognosis in superficial bladder cancer Sem. Urol. 10:28-38, 1992.
220. 1992 Cancer de la vessie: un point de convergence biologique et clinique Association des Medecins de Langue française du Canada, 1992, pp. 71-78.
221. 1991 Contemporary management of bladder cancer. Canadian Family Physician, 37: 1469-1477, 1991.
222. 1991 Chemotherapy in bladder cancer. Contemporary Urology 2: 6-12, 1991.
223. 1991 Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder J. Urol. 146: 1631-1636, 1991.
224. 1991 Molecular and immunologic approaches in the management of bladder cancer. Urol. Clin. North Am. 18: 515-525, 1991.
225. 1991 Precision of DNA flow cytometry in inter-institutional analyses. Cytometry, 12:405-412, 1991.
226. 1991 Role de la prostatectomie radicale et nouvelles perspectives dans le traitement du cancer localist de la prostate. D & D Medical, Paris, 1991, pp. 9-17.
227. 1991 Etude comparative de la castration seule et avec nilutamide dans le traitement du cancer metastatique de la prostate Dans: Le Traitement du Cancer de la Prostate, Ed. D & D Medical, Paris, 1991, pp. 169-177.
228. 1991 DNA slit-scan flow cytometry of bladder irrigation specimens and the importance of recognizing urothelial cells Cytometry, 12:140-146, 1991
229. 1991 Total androgen ablation: Canadian experience Urol. Clin. North Am. 18:75-82, 1991.
230. 1990 Signification clinique et biologique des antigenes tumoraux associes au cancer de la vessie Union Med. Canada 119:291, 1990.
231. 1990 Histopathology of renal cell carcinoma, nephroblastoma, hamartoma and oncocytoma. In: Scientific foundations in Urology Chisholm G & Fair WR, Eds, 1990, pp. 516-522.
232. 1990 A controlled trial of castration with and without Nilutamide in metastatic prostatic carcinoma. Cancer 66:1074-1079, 1990.
233. 1990 Monoclonal antibody against a tumor-associated sialoglycoprotein of superficial papillary bladder tumors and cervical condylomas. Int. J. Cancer 46:990-997, 1990.
234. 1990 Biological markers of prognosis in invasive bladder cancer Semin. Oncology, 17:533-543, 1990.
235. 1990 The assessment of disease aggressivity in Stage D2 cancer patients (Review). Anticancer Res. 10: 333-336, 1990.
236. 1990 Growth regulated cell surface glycoproteins of human bladder cancer. Cancer Res. 50:293-298, 1990.
237. 1990 Clinical cancer progression in urinary bladder tumors: evaluation by multiparameter flow cytometry with monoclonal antibodies. Cancer Res. 50:432-437, 1990
238. 1989 Molecular markers of superficial and aggressive human bladder cancers Proc. Amer. Ass. Cancer Res. 30: 662 663, 1989.
239. 1989 Total androgen blockade in stage D2 prostatic cancer - a randomized trial. In: Actualizaciones Urologicas. J.Edson Pontes, Ed. Pulso Ediciones, 1989, pp 87, 94.
240. 1988 Comparison of total androgen blockade and orchiectomy in metastatic cancer of prostate. In: A multidisciplinary analysis of controversies in the management of prostate cancer. New York: Plenum Press, 1988, 225, 232
241. 1988 Total androgen blockade versus castration in metastatic cancer of the prostate. In: Hormonal therapy of prostatic diseases: Basic and clinical aspects Motta M & Serio M, Eds., Amsterdam, Medicom Europe, 1988, 302 311.
242. 1987 Polymorphic expression of a human superficial bladder tumor antigen defined by mouse monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 84:7227 7231, 1987.
243. 1987 Total androgen blockade vs orchiectomy in stage D2 prostate cancer. Prog. Clin. Biol. Res., 243A: 391, 400, 1987.
244. 1987 Total androgen blockade vs orchiectomy in stage D prostate cancer. In: Prostate cancer, Part A: research endocrine treatment and histopathology. New York: Alan R. Liss, 1987, pp.391 400
245. 1986 Cell surface antigens of human bladder tumors: definition of tumor subsets by monoclonal antibodies and correlation with growth characteristics. Cancer Res. 46: 5183, 1986.


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.